HAYWARD, Calif., March 4, 2026
Pulse Biosciences announced that its nPulse™ Vybrance™ System, powered by proprietary Nanosecond Pulsed Field Ablation (nsPFA™) technology, will be highlighted in multiple scientific presentations at the North American Society for Interventional Thyroidology (NASIT) 2026 meeting. The presentations will showcase clinical feasibility data and long-term follow-up outcomes for the use of non-thermal ablation technology in the treatment of benign thyroid nodules, a condition affecting millions of patients worldwide. The upcoming conference sessions will present data demonstrating durable symptom improvement and sustained thyroid nodule volume reduction, reinforcing the potential of bioelectric medicine to transform minimally invasive treatment approaches in endocrine and interventional medicine.
Clinical Study Highlights Long-Term Feasibility Results
The scientific presentations will focus on the clinical feasibility study evaluating the use of the nPulse Vybrance System for the treatment of benign, symptomatic thyroid nodules. According to investigators involved in the research, the system uses ultra-short pulses of electrical energy to selectively destroy targeted cells while preserving surrounding connective and structural tissue, representing a significant shift from conventional thermal ablation methods.
Researchers will present long-term follow-up data from patients treated in the initial feasibility study, with monitoring extending up to 22 months after treatment. These results indicate that patients experienced durable reduction in thyroid nodule size and improvement in associated symptoms, suggesting that nanosecond pulsed field ablation may offer a safe and effective non-thermal approach for managing benign thyroid nodules.
The podium presentation scheduled during the Clinical Science Session will review the durability of treatment outcomes between 15 and 22 months following the procedure, offering valuable insights into the potential long-term clinical benefits of the technology. Investigators believe that continued evaluation of patient outcomes will help determine whether the therapy can become a viable alternative to surgery or traditional thermal ablation techniques.
Advertisement
Non-Thermal Bioelectric Technology for Precision Treatment
The nPulse Vybrance System is based on Pulse Biosciences’ proprietary Nanosecond Pulsed Field Ablation technology, which delivers extremely short bursts of electrical energy to targeted tissue. Unlike thermal ablation approaches such as radiofrequency or microwave treatments that destroy tissue through heat, nsPFA technology operates through a non-thermal mechanism that disrupts cellular membranes while sparing surrounding non-cellular structures.
This selective mechanism enables physicians to precisely eliminate abnormal or unwanted cells while preserving important structures such as blood vessels, nerves, and connective tissue. As a result, the technology may reduce the risk of complications often associated with thermal ablation procedures, including tissue scarring and unintended damage to nearby structures.
The system’s application in thyroid nodule treatment is particularly significant because the thyroid gland is located near sensitive structures such as the recurrent laryngeal nerve and major blood vessels, making precise and controlled treatment methods especially important.
Scientific Presentations at NASIT 2026
The nPulse technology will be featured in both a scientific podium presentation and a product theatre discussion during the NASIT 2026 conference, which brings together leading experts in interventional thyroidology and minimally invasive endocrine procedures.
The podium presentation will highlight the clinical feasibility study results and long-term patient follow-up data, while the product theatre session will feature a roundtable discussion led by experienced clinicians who have used the technology in clinical practice. The panel will examine the mechanism of action of nsPFA technology, clinical outcomes observed in treated patients, and case studies demonstrating real-world use of the system.
Researchers and clinicians participating in the discussion will also explore the future potential of nanosecond pulsed field ablation in additional therapeutic areas, including cardiac applications such as atrial fibrillation and other soft-tissue ablation procedures.
Advancing the Field of Bioelectric Medicine
Pulse Biosciences is part of a growing group of companies focused on bioelectric medicine, an emerging field that uses targeted electrical energy to treat disease and modify biological processes. By leveraging advanced energy delivery technologies, researchers aim to develop less invasive and more precise treatments that improve patient outcomes while minimizing side effects.
The continued clinical investigation of the nPulse Vybrance System highlights the expanding role of energy-based medical technologies in modern healthcare, particularly in areas where traditional surgical approaches may carry significant risks.
As additional clinical data become available and larger studies are conducted, nanosecond pulsed field ablation may emerge as a promising next-generation treatment option for patients with benign thyroid nodules and other soft-tissue conditions.
The upcoming NASIT presentations are expected to provide important insights into the clinical potential and long-term effectiveness of this innovative non-thermal ablation technology, further advancing research in the rapidly evolving field of bioelectric medicine.
z
Source: Pulse Biosciences, Inc. press release
